152 related articles for article (PubMed ID: 36994207)
1. High-throughput drug screening identifies fluoxetine as a potential therapeutic agent for neuroendocrine prostate cancer.
Chen L; Ji Y; Li A; Liu B; Shen K; Su R; Ma Z; Zhang W; Wang Q; Zhu Y; Xue W
Front Oncol; 2023; 13():1085569. PubMed ID: 36994207
[TBL] [Abstract][Full Text] [Related]
2. Repurposing ketotifen as a therapeutic strategy for neuroendocrine prostate cancer by targeting the IL-6/STAT3 pathway.
Ji Y; Liu B; Chen L; Li A; Shen K; Su R; Zhang W; Zhu Y; Wang Q; Xue W
Cell Oncol (Dordr); 2023 Oct; 46(5):1445-1456. PubMed ID: 37120492
[TBL] [Abstract][Full Text] [Related]
3. A Drug Repurposing Screen Identifies Fludarabine Phosphate as a Potential Therapeutic Agent for N-MYC Overexpressing Neuroendocrine Prostate Cancers.
Elhasasna H; Khan R; Bhanumathy KK; Vizeacoumar FS; Walke P; Bautista M; Dahiya DK; Maranda V; Patel H; Balagopal A; Alli N; Krishnan A; Freywald A; Vizeacoumar FJ
Cells; 2022 Jul; 11(14):. PubMed ID: 35883689
[TBL] [Abstract][Full Text] [Related]
4. Specific classification and new therapeutic targets for neuroendocrine prostate cancer: A patient-based, diagnostic study.
Wang Y; Wu N; Wang K; Liao Y; Guo J; Zhong B; Guo T; Liang J; Jiang N
Front Genet; 2022; 13():955133. PubMed ID: 36118857
[No Abstract] [Full Text] [Related]
5. Addressing the need for more therapeutic options in neuroendocrine prostate cancer.
Kemble J; Kwon ED; Karnes RJ
Expert Rev Anticancer Ther; 2023 Feb; 23(2):177-185. PubMed ID: 36698089
[TBL] [Abstract][Full Text] [Related]
6. Icaritin suppresses development of neuroendocrine differentiation of prostate cancer through inhibition of IL-6/STAT3 and Aurora kinase A pathways in TRAMP mice.
Sun F; Zhang ZW; Tan EM; Lim ZLR; Li Y; Wang XC; Chua SE; Li J; Cheung E; Yong EL
Carcinogenesis; 2016 Jul; 37(7):701-711. PubMed ID: 27207661
[TBL] [Abstract][Full Text] [Related]
7. SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.
Li Y; Donmez N; Sahinalp C; Xie N; Wang Y; Xue H; Mo F; Beltran H; Gleave M; Wang Y; Collins C; Dong X
Eur Urol; 2017 Jan; 71(1):68-78. PubMed ID: 27180064
[TBL] [Abstract][Full Text] [Related]
8. LIN28B promotes the development of neuroendocrine prostate cancer.
Lovnicki J; Gan Y; Feng T; Li Y; Xie N; Ho CH; Lee AR; Chen X; Nappi L; Han B; Fazli L; Huang J; Gleave ME; Dong X
J Clin Invest; 2020 Oct; 130(10):5338-5348. PubMed ID: 32634132
[TBL] [Abstract][Full Text] [Related]
9. MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer.
Hsu EC; Shen M; Aslan M; Liu S; Kumar M; Garcia-Marques F; Nguyen HM; Nolley R; Pitteri SJ; Corey E; Brooks JD; Stoyanova T
Sci Rep; 2021 Jun; 11(1):13305. PubMed ID: 34172788
[TBL] [Abstract][Full Text] [Related]
10. Activated ALK Cooperates with N-Myc via Wnt/β-Catenin Signaling to Induce Neuroendocrine Prostate Cancer.
Unno K; Chalmers ZR; Pamarthy S; Vatapalli R; Rodriguez Y; Lysy B; Mok H; Sagar V; Han H; Yoo YA; Ku SY; Beltran H; Zhao Y; Abdulkadir SA
Cancer Res; 2021 Apr; 81(8):2157-2170. PubMed ID: 33637566
[TBL] [Abstract][Full Text] [Related]
11. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.
Bishop JL; Thaper D; Vahid S; Davies A; Ketola K; Kuruma H; Jama R; Nip KM; Angeles A; Johnson F; Wyatt AW; Fazli L; Gleave ME; Lin D; Rubin MA; Collins CC; Wang Y; Beltran H; Zoubeidi A
Cancer Discov; 2017 Jan; 7(1):54-71. PubMed ID: 27784708
[TBL] [Abstract][Full Text] [Related]
12. Systems Medicine Approaches to Improving Understanding, Treatment, and Clinical Management of Neuroendocrine Prostate Cancer.
Yadav KK; Shameer K; Readhead B; Yadav SS; Li L; Kasarskis A; Tewari AK; Dudley JT
Curr Pharm Des; 2016; 22(34):5234-5248. PubMed ID: 27174811
[TBL] [Abstract][Full Text] [Related]
13. Polycomb-mediated silencing in neuroendocrine prostate cancer.
Clermont PL; Lin D; Crea F; Wu R; Xue H; Wang Y; Thu KL; Lam WL; Collins CC; Wang Y; Helgason CD
Clin Epigenetics; 2015; 7(1):40. PubMed ID: 25859291
[TBL] [Abstract][Full Text] [Related]
14. Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer.
Lin D; Dong X; Wang K; Wyatt AW; Crea F; Xue H; Wang Y; Wu R; Bell RH; Haegert A; Brahmbhatt S; Hurtado-Coll A; Gout PW; Fazli L; Gleave ME; Collins CC; Wang Y
Oncotarget; 2015 Jan; 6(3):1806-20. PubMed ID: 25544761
[TBL] [Abstract][Full Text] [Related]
15. Advances in neuroendocrine prostate cancer research: From model construction to molecular network analyses.
Shui X; Xu R; Zhang C; Meng H; Zhao J; Shi C
Lab Invest; 2022 Apr; 102(4):332-340. PubMed ID: 34937865
[TBL] [Abstract][Full Text] [Related]
16. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.
Ramnarine VR; Alshalalfa M; Mo F; Nabavi N; Erho N; Takhar M; Shukin R; Brahmbhatt S; Gawronski A; Kobelev M; Nouri M; Lin D; Tsai H; Lotan TL; Karnes RJ; Rubin MA; Zoubeidi A; Gleave ME; Sahinalp C; Wyatt AW; Volik SV; Beltran H; Davicioni E; Wang Y; Collins CC
Gigascience; 2018 Jun; 7(6):. PubMed ID: 29757368
[TBL] [Abstract][Full Text] [Related]
17. Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer.
Wang J; Xu W; Mierxiati A; Huang Y; Wei Y; Lin G; Dai B; Freedland SJ; Qin X; Zhu Y; Ye DW
Prostate; 2019 Sep; 79(13):1563-1571. PubMed ID: 31376193
[TBL] [Abstract][Full Text] [Related]
18. Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer.
DeLucia DC; Cardillo TM; Ang L; Labrecque MP; Zhang A; Hopkins JE; De Sarkar N; Coleman I; da Costa RMG; Corey E; True LD; Haffner MC; Schweizer MT; Morrissey C; Nelson PS; Lee JK
Clin Cancer Res; 2021 Feb; 27(3):759-774. PubMed ID: 33199493
[TBL] [Abstract][Full Text] [Related]
19. Establishment of a neuroendocrine prostate cancer model driven by the RNA splicing factor SRRM4.
Li Y; Chen R; Bowden M; Mo F; Lin YY; Gleave M; Collins C; Dong X
Oncotarget; 2017 Sep; 8(40):66878-66888. PubMed ID: 28978002
[TBL] [Abstract][Full Text] [Related]
20. Targeting Wnt/EZH2/microRNA-708 signaling pathway inhibits neuroendocrine differentiation in prostate cancer.
Shan J; Al-Muftah MA; Al-Kowari MK; Abuaqel SWJ; Al-Rumaihi K; Al-Bozom I; Li P; Chouchane L
Cell Death Discov; 2019; 5():139. PubMed ID: 31583122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
